PET Scan
From Ascites to Malignant Peritoneal Mesothelioma: The Diagnostic Workup of a Rare Tumor
Cancer Diagnosis & Prognosis 2026 July 1 [Link] Mirko Nastasi, Chiara Ferrante, Giuliana Michelis, Enrica Branca, Manuel Ventura, Silvia Novello, Emanuela Laurita Abstract Background/aim: Ascites is a common clinical manifestation of a wide spectrum of heterogeneous underlying conditions. All possible causes of ascites should be considered in the differential diagnosis to ensure an appropriate diagnostic…
Read MoreDual-time-point [18F]FDG-PET/CT as a prognostic biomarker in patients with pleural mesothelioma undergoing immunotherapy
EJNMMI Research 2026 June 20 [Link] Solfrid Thunold, Eivor Hernes, Lars Tore Gyland Mikalsen, Saima Farooqi, Åsa Kristina Öjlert, Roslyn J Francis, Anna K Nowak, Weronika Maria Szejniuk, Søren Steen Nielsen, Susana Cedres, Marc Simo Perdigo, Jens Benn Sørensen, Carin Meltzer, Åslaug Helland, Eirik Malinen, Vilde Drageset Haakensen Abstract Background: [18F]FDG PET/CT provides a non-invasive…
Read MoreThe diagnostic performance and clinical value of [18F]FDG PET/CT in pleural mesothelioma – A systematic review and meta-analysis
Seminars in Nuclear Medicine 2026 June 10 [Link] Anne H Thostrup, Natasja U Stubbe, Mathias P Schreiner, Morten Bentestuen, Anne V Olesen, Helle D Zacho Abstract Purpose: This systematic review and meta-analysis aims to evaluate the diagnostic accuracy of FDG PET/CT for diagnosing pleural mesothelioma in treatment-naïve patients using histopathology as reference standard. Secondary aims…
Read MoreEmerging Strategies in the Diagnosis and Treatment of Pleural Mesothelioma: An Overview
Thoracic Cancer 2026 April [Link] Raffaella Pagliaro, Beatrice Leonardi, Angela Schiattarella, Grazia Bergameo, Carmine Picone, Adolfo Gallipoli D’Errico, Filippo Scialò, Fabio Perrotta, Maria Luisa De Rimini, Alfonso Fiorelli, Andrea Bianco Abstract Pleural mesothelioma (PM) is a rare and aggressive cancer arising from pleural mesothelial cells with a strong association to asbestos exposure. Among the diagnostic…
Read MoreCase Report: Immune checkpoint inhibitor-triggered anti-Ma2 paraneoplastic encephalitis in sarcomatoid pleural mesothelioma: a fatal case
Frontiers in Oncology 2026 March 9 [Link] Ilker Nihat Okten, Tuba Baydaş Abstract Background: Neurological immune-related adverse events (N-irAEs) represent rare but potentially fatal complications of immune checkpoint inhibitor (ICI) therapy. Among these, encephalitis associated with paraneoplatic neuronal antibodies poses a major diagnostic and therapeutic challenge, as it blurs the distinction between drug-induced toxicity and…
Read MorePretreatment volume-based 18F-FDG PET/CT parameters as prognostic indicators in malignant peritoneal mesothelioma patients
Japanese Journal of Radiology 2026 March 21 [Link] Kazuhiro Kitajima, Kosuke Matsuda, Hiroyuki Yokoyama, Toshiyuki Minami, Akifumi Nakamura, Kozo Kuribayashi, Takashi Kijima, Koichiro Yamakado Abstract Objective: This study was conducted to examine relationships of pretreatment volume-based quantitative 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) parameters with overall survival (OS) in malignant peritoneal mesothelioma (MPeM) patients.…
Read MoreMalignant Pleural Mesothelioma (MPM) Evaluation with [11C]-Methionine PET/CT Before and After Talc Pleurodesis
Molecular Imaging and Biology 2026 March 9 [Link] Egesta Lopci, Angelo Castello, Alberto Testori, Emanuele Voulaz, Daoud Rahal 5, Matteo Perrino 6, Alessandro Crepaldi 3, Giorgio Maria Ferraroli 3, Valentina Errico 3, Edoardo Bottoni 3, Marcello Rodari 7, Lorenzo Muraglia 2, Giuseppe Marulli 3 4, Marco Alloisio, Paolo Andrea Zucali Abstract Background: Malignant pleural mesothelioma…
Read MoreBAP-1 in the diagnosis of malignant pleural mesothelioma
Respiratory Medicine and Research 2025 November 28 [Link] Irene Sansano, Ana Vázquez, Oscar Persiva, Marc Simó, Leire Sánchez, Pilar Montoya, Carme Dinarès, Carmen Alemán Abstract Background: The diagnosis of malignant pleural mesothelioma (MPM) can be challenging for clinicians and pathologists. Patients and methods: This study included all patients diagnosed with pleural mesothelioma between October 2013…
Read MoreDisaster on MARS2? Lessons Learned from Modern Day Outcomes of Surgery for Pleural Mesothelioma
The Annals of Thoracic Surgery 2026 February 2 [Link] Shubham Gulati, Andrea Wolf, Jai Mehrotra-Varma, Stephanie Tuminello, Emanuela Taioli, Raja Flores Abstract Background: The Mesothelioma and Radical Surgery 2 (MARS2) trial has drawn into question pleurectomy/decortication (PD) for the treatment of pleural mesothelioma. This trial’s evaluation of resectability (poor positron emission tomography/computed tomography utilization, patients…
Read MoreArtificial Intelligence in Pleural Diseases: Current Applications and Next Steps
Thoracic Research and Practice 2026 January 30 [Link] Ferhan Karataş, Öner Dikensoy Abstract Pleural diseases pose a significant burden on healthcare systems due to diagnostic challenges and high costs. Artificial intelligence (AI) has the potential to provide faster, more accurate, and more reliable results in the diagnosis of these diseases. This review evaluates the current…
Read More
Skip to content